Immatics Biotechnologies lands 1.1bn deal with GSK
US-German immunooncology specialist Immatics Biotechnologies GmbH has licensed two of its TCR-T programs to GlaxoSmithKline for US$50m upfront.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1165 entries already.
Entries by Thomas Gabrielczyk
KKR backs Belgian tech provider Univercells SA
/in News/by Thomas GabrielczykUnivercells S.A. cashes in up to 50m from the KKR subsidiary Gamma Bioscience to advance its gene and cell therapy manufacturing platform.
EU diagnostic labs prepared for Sars-CoV-2
/in News/by Thomas GabrielczykShortly before a EU health ministers discuss the spread of the Chinese coronavirus, EU diagnostic labs have considered themselves prepared for a possible Sars-CoV-2 epidemic.
PharmaMar/Jazz Pharmaceuticals get NDA priority for lung cancer drug
/in News/by Thomas GabrielczykPharmaMar and Jazz Pharmaceuticals have received FDA Priority Review of a NDA for lurbinectedin in relapsed SCLC (Small Cell Lung Cancer).
Diabetes combo improves regeneration of beta cells
/in News/by Thomas GabrielczykUsing a combination of approved diabetes drugs, a Swiss-US research team was able to support the regeneration of insulin-secreting cells in the pancreas.
JAKPot for treating bone loss
/in News/by Thomas GabrielczykResearchers report that JAK inhibitors a class of approved anti-inflammatory drugs prevented bone loss in mice with osteoporosis and two patients with rheumatoid arthritis.
Mereo BioPharma raise money to back Phase III trials
/in News/by Thomas GabrielczykMereo BioPharma has entered into a $5m convertible equity financing with Novartis and a $28m securities purchase agreement with Aspire Capital Fund.
BIH scientists optimise CRISPR gene scissors
/in News/by Thomas GabrielczykTargeted genome editing using the CRISPR-Cas9 system is easy to use but far from being perfect. Computer calculated modification of CRISPR activity can reduce "off-target effects".
Azafaros BV raises 25m in Series A round
/in News/by Thomas GabrielczykDutch biotech Azafaros B.V. has closed a 25m Series A financing round.
Researchers identify roots of childhood asthma
/in News/by Thomas GabrielczykInfants who show defective immune responses to microbial components are more likely to acquire asthma later in childhood, according to a study of 541 children.